Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis
Authors:
Open Access
- 10 September 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11
Abstract
Galectin-3 (Gal-3) is an extracellular matrix glycan-binding protein with several immunosuppressive and pro-tumor functions. The role of Galectin-3 in cancer stem-like cells (CSCs) is poorly investigated. Here, we show that prostate CSCs also colonizing prostate-draining lymph nodes of transgenic adenocarcinoma of the mouse prostate (TRAMP) mice overexpress Gal-3. Gal-3 contributes to prostate CSC-mediated immune suppression because either Gal-3 silencing in CSCs, or co-culture of CSCs and T cells in the presence of the Gal-3 inhibitor N-Acetyl-D-lactosamine rescued T cell proliferation. N-Acetyl-D-lactosamine also rescued the proliferation of T cells in prostate-draining lymph nodes of TRAMP mice affected by prostate intraepithelial neoplasia. Additionally, Gal-3 impacted prostate CSC tumorigenic and metastatic potential in vivo, as Gal-3 silencing in prostate CSCs reduced both primary tumor growth and secondary invasion. Gal-3 was also found expressed in more differentiated prostate cancer cells, but with different intracellular distribution as compared to CSCs, which suggests different functions of Gal-3 in the two cell populations. In fact, the prevalent nuclear and cytoplasmic distribution of Gal-3 in prostate CSCs made them less susceptible to apoptosis, when compared to more differentiated prostate cancer cells, in which Gal-3 was predominantly intra-cytoplasmic. Finally, we found Gal-3 expressed in human and mouse prostate intraepithelial neoplasia lesions and in metastatic lymph nodes. All together, these findings identify Gal-3 as a key molecule and a potential therapeutic target already in the early phases of prostate cancer progression and metastasis.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro
This publication has 82 references indexed in Scilit:
- Gene Signatures Distinguish Stage-Specific Prostate Cancer Stem Cells Isolated From Transgenic Adenocarcinoma of the Mouse Prostate Lesions and Predict the Malignancy of Human TumorsStem Cells Translational Medicine, 2013
- Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responsesOncoImmunology, 2013
- Unmasking the immune recognition of prostate cancer with CTLA4 blockadeNature Reviews Cancer, 2012
- Galectin-3 negatively regulates TCR-mediated CD4+T-cell activation at the immunological synapseProceedings of the National Academy of Sciences, 2009
- Galectin‐3 regulates T‐cell functionsImmunological Reviews, 2009
- Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer ModelCancer Research, 2009
- Regulation of Prostate Cancer Progression by Galectin-3The American Journal of Pathology, 2009
- Ligand Reduces Galectin-1 Sensitivity to Oxidative Inactivation by Enhancing Dimer FormationJournal of Biological Chemistry, 2009
- Galectin Binding to Mgat5-Modified N-Glycans Regulates Fibronectin Matrix Remodeling in Tumor CellsMolecular and Cellular Biology, 2006
- Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunizationEuropean Journal of Immunology, 2004